GBA3抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: LOVO cell lysate, Primary antibody: P10494(GBA3 Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P10494(GBA3 Antibody) at dilution 1/160. (Original magnification: ×200)    

  
  

The GBA3 antibody targets the enzyme cytosolic β-glucosidase (GBA3), encoded by the GBA3 gene in humans. This enzyme belongs to the glycoside hydrolase family and hydrolyzes β-glucosidic bonds in various substrates, including glycosphingolipids, flavonoid glycosides, and xenobiotics. Unlike its lysosomal homolog GBA1 (glucocerebrosidase), which is linked to Gaucher disease and Parkinson’s disease, GBA3 operates in the cytosol and is implicated in alternative pathways of glycolipid metabolism. Research suggests GBA3 may compensate for GBA1 dysfunction in certain contexts, though its precise physiological role remains under investigation.

GBA3 antibodies are critical tools for studying the enzyme’s expression, localization, and function in cellular models and tissues. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Dysregulation of GBA3 has been explored in neurodegenerative diseases, cancer, and metabolic disorders, with antibodies aiding in correlating enzyme levels to pathological states. Additionally, GBA3 antibodies support drug discovery efforts, particularly in developing inhibitors or modulators for therapeutic interventions. Recent studies also highlight its potential role in activating prodrugs or detoxifying glycosylated compounds, expanding its relevance in pharmacology. Overall, GBA3 antibodies are vital for unraveling the enzyme’s biological significance and translational applications.